Cargando…
Targeting HTLV-1 Activation of NFκB in Mouse Models and ATLL Patients
Of the millions of HTLV-1 infected carriers worldwide, 3–5% will develop an aggressive T-cell neoplasm that is highly refractory to conventional therapy. The virus carries the Tax oncogene which constitutively activates the NFκB pathway. This co-option of signaling through NFκB provides for the HTLV...
Autores principales: | Rauch, Daniel A., Ratner, Lee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185776/ https://www.ncbi.nlm.nih.gov/pubmed/21994759 http://dx.doi.org/10.3390/v3060886 |
Ejemplares similares
-
Arsenic trioxyde in the treatment of HTLV1 associated ATLL
por: Suarez, Felipe, et al.
Publicado: (2011) -
HTLV-1, ATLL, refractory hypercalcaemia and HIV-1 co-infection
por: Laher, Abdullah E, et al.
Publicado: (2018) -
Targeting NF-κB with Nanotherapy in a Mouse Model of Adult T-Cell Leukemia/Lymphoma
por: Rauch, Daniel A., et al.
Publicado: (2021) -
The Emerging Role of miRNAs in HTLV-1 Infection and ATLL Pathogenesis
por: Moles, Ramona, et al.
Publicado: (2015) -
HTLV-1, ATLL, severe hypercalcaemia and HIV-1 co-infection: an overview
por: Laher, Abdullah Ebrahim, et al.
Publicado: (2018)